Inspection Defense Package · Worked sample
One GMP decision. Five documents. This is what you receive.
Built from a real CAPA effectiveness closure. Every submission generates:
- ✓ Executive Brief
- ✓ Defensibility Analysis
- ✓ Response Kit
- ✓ Investigator Challenge Guide
- ✓ Authorization Record
The scenario is fictitious; the format is exactly what you receive for your own decision. Nothing is invented — every line is built from the inputs you submit. Gaps are flagged, not hidden.
The decision under inspection
A quality director closed a CAPA after a 90-day effectiveness window, concluding a recurring environmental-monitoring excursion had been corrected. Months later, an investigator asks the question the CAPA record can't answer on its own:
“How did you determine CAPA-2025-0118 was effective? What evidence supported closure, and on what basis was it closed when it was?”
Here is the package that answers it.
01 · Executive Brief
The 15-second read.
- Document an independent effectiveness review
- Justify the 90-day verification window
- Exclude alternative recurrence causes
02 · Defensibility Analysis
Will this survive inspection?
The closure is substantively sound — 90 days of monitoring showed zero recurrence — but the record relies on a single authority, asserts the verification window without justifying it, and does not show alternative causes were ruled out. An investigator can reopen the closure on any of the three. This is documentation exposure, not an ineffective CAPA.
Critical exposure
- Closure was authorized by a single individual. No independent reviewer is recorded, leaving the effectiveness conclusion uncorroborated under 21 CFR 211.192.
Reconstruction risk
- The 90-day verification window is stated but not justified. An investigator can ask why 90 days was sufficient for this failure mode, and the record cannot answer.
- Alternative recurrence pathways — procedural drift, analyst turnover, seasonal variation — are not documented as considered and ruled out.
Evidence matrix
03 · Response Kit
Ready-to-use record language.
The exact language that closes each gap — written from your record, ready to paste. It doesn't tell you what to fix. It writes the fix.
04 · Investigator Challenge Guide
The questions to rehearse.
Q1How did you determine CAPA-2025-0118 was effective, and on what basis was it closed when it was?
Closure was authorized by P. Trubl, Director Quality Systems & CAPA, on 12-AUG-2025, after a 90-day verification window in which environmental monitoring recorded zero excursions in the affected aseptic area. Effectiveness rested on three convergent streams — the EM trend, completed analyst retraining, and revised procedure SOP-EM-318 R04 — with an independent audit observation at day 65 confirming compliance.
Q2Why was a 90-day window sufficient to conclude the corrective action was effective?
Ninety days spanned more than two full environmental-monitoring cycles and thirteen weekly QA reviews, covering the analyst-workload and shift variability present when the original excursion occurred. The window was defined prospectively, before implementation, and was long enough to surface recurrence had the action failed.
Q3What alternative explanations for the absence of recurrence did you consider and rule out?
Procedural drift was ruled out by a day-65 internal audit observing compliant execution; analyst turnover was ruled out because the retrained roster stayed intact; and facility or seasonal variation was ruled out by the absence of excursions in adjacent classified areas over the same period. Absence of recurrence alone was not treated as proof of effectiveness.
05 · Authorization Record
CAPA Effectiveness Closure · CAPA-2025-0118 · originating deviation DEV-2025-0042
§01 Investigator Question
How did you determine CAPA-2025-0118 was effective? What evidence supported closure, and on what basis was it closed when it was?
§02 Authorization Summary
P. Trubl, Director Quality Systems & CAPA, authorized closure of CAPA-2025-0118 on 12-AUG-2025, concluding that the corrective action — revised procedure SOP-EM-318 R04 and analyst retraining — effectively reduced recurrence risk for the environmental-monitoring excursion originating in DEV-2025-0042.
§03 Evidence Reviewed
- Environmental-monitoring trend — 90 days, zero excursions [primary]
- Analyst retraining records — roster requalified [supporting]
- SOP-EM-318 R04 — procedural control revised [supporting]
- Internal audit observation at day 65 — compliant execution [corroborating]
§04 Risk Evaluation
Known risk: recurrence of the environmental-monitoring excursion and associated contamination risk in the aseptic area. Residual risk: low — zero recurrence across a 90-day window spanning more than two monitoring cycles. Patient and product impact: none observed. Residual risk was accepted because three convergent evidence streams supported the effectiveness conclusion and routine controls continue post-closure.
§05 Alternatives Considered
Extending the verification window — rejected; 90 days already spanned more than two full monitoring cycles. Deferring closure pending the next scheduled audit — rejected; the day-65 audit had already confirmed compliant execution. Closure with continued routine monitoring was selected as the disposition consistent with the evidence.
§06 Authorization Rationale
The effectiveness conclusion rested on convergent evidence rather than absence of recurrence alone: a 90-day EM trend with zero excursions, completed retraining of the analyst roster, the revised procedure in force, and an independent audit observation confirming the procedure was executed as written. The window was defined prospectively and covered the variability under which the original excursion occurred. On the weight of that convergence, closure was justified at the time it was authorized.
§07 Regulatory Alignment
21 CFR 211.192 (production record review and CAPA); 21 CFR 211.100 (written procedures; deviations); 21 CFR 211.113 (control of microbiological contamination); ICH Q10 (pharmaceutical quality system). Effectiveness closure is recognized where a defined verification window, convergent evidence, and a documented effectiveness conclusion support the determination.
§08 Residual Exposure Statement
Remaining uncertainty: theoretical recurrence under conditions not represented in the window — new analysts added post-window, equipment maintenance, or a change in monitoring media. Monitoring commitment: daily EM logging and weekly QA review continue as routine GMP beyond closure.
§09 Reconstruction Prevention Statement
This record was generated to document the authorization rationale contemporaneously with the operational decision in order to prevent post-inspection reconstruction of release justification.
§10 Known Limitations
Closure was authorized by a single authority; an independent effectiveness review is added in the Response Kit above. The verification-window justification and the exclusion of alternative recurrence causes were not present in the original record; both are addressed in the Response Kit. Assumes the environmental-monitoring method remained in its validated state across the window.
This package reflects structured inputs only. The named decision owner is the authorizing party. ComplianceWorxs is the recording medium, not the authorizer. Scenario and identifiers are fictitious.
Document the reasoning before the inspector asks.
You answer the questions about your decision — about fifteen minutes. The package is generated from your inputs, gaps flagged, nothing invented, delivered on screen to save or print as a single QMS-uploadable PDF.
Defend One GMP Decision — $497 →Executive Brief · Defensibility Analysis · Response Kit · Investigator Challenge Guide · Authorization Record